• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alvotech - Ordinary Shares (NQ:ALVO)

    5.210 +0.020 (+0.39%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Alvotech - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    News headline image
    Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech to present at upcoming investor conferences in September
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
    From Alvotech
    Via GlobeNewswire
    Alvotech (NASDAQ:ALVO) Q1 2026 Results Miss Estimates, Shares Drop Over 9% as Revenue and EPS Fall Short ↗
    Via Chartmill
    News headline image
    Alvotech Q2 Earnings Call Highlights ↗
    Alvotech (NASDAQ:ALVO) said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Alvotech Q2 2026 Earnings Call Transcript ↗
    Alvotech (NASDAQ:ALVO) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga... 
    Via Benzinga
    Topics Earnings
    News headline image
    Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech to Report Financial Results for H1 2026
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech announces successful closure of FDA inspection of manufacturing facility
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech further strengthens liquidity by securing term loan facility of $75 million
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
    From Alvotech
    Via GlobeNewswire
    These stocks are moving in today's after hours session ↗
    Via Chartmill
    News headline image
    Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
    From Alvotech
    Via GlobeNewswire
    News headline image
    Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? ↗
    Driving revenue growth and earnings growth are two different things. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions ↗
    Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilars-focused company is entering a “critical inflection period” as it advances several limited-competition products through... 
    Via MarketBeat
    News headline image
    Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End ↗
    Alvotech (NASDAQ:ALVO) is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global... 
    Via MarketBeat
    News headline image
    Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
    From Alvotech
    Via GlobeNewswire
    News headline image
    Main Results of 2026 Annual and Extraordinary General Meeting
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech to present at upcoming investor conferences in June
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech (ALVO) Q4 2025 Earnings Transcript ↗
    Alvotech (ALVO) Q4 2025 Earnings Transcript 
    Via The Motley Fool
    Topics Bonds
    News headline image
    Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End ↗
    Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics license applications to the U.S. Food and Drug Administration in June... 
    Via MarketBeat
    News headline image
    Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech (ALVO) Q1 2026 Earnings Transcript ↗
    Alvotech (ALVO) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Alvotech Q1 2026 Financial Results
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech Announces a Change in its Executive Team
    From Alvotech
    Via GlobeNewswire
    News headline image
    Alvotech to Report Financial Results for the First Quarter of 2026
    From Alvotech
    Via GlobeNewswire
    Wondering what's happening in today's after-hours session? ↗
    Via Chartmill
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.